Internal Medicine Alert
RSSArticles
-
Dihydroergotamine Nasal Spray (Trudhesa)
DHE nasal spray can be prescribed to treat migraine in adults with or without aura.
-
Iron Therapy for Acute Heart Failure
Giving intravenous ferric carboxymaltose to stabilized post-acute heart failure patients with iron deficiency improved quality of life vs. placebo-treated patients within four weeks, which persisted during subsequent therapy for up to 24 weeks.
-
Proton-Pump Inhibitors and Community-Associated Clostridioides difficile Infection
A nationwide cohort study of adults in Denmark found that proton-pump inhibitor (PPI) use was associated with a moderately increased risk of community-associated Clostridioides difficile infection, and the risk remained elevated up to one year after PPI treatment had ended.
-
Clostridioides difficile Infection: Guideline Update
Fidaxomicin is preferred over vancomycin for initial and recurrent cases. Bezlotoxumab is recommended in many cases of recurrent infection and initial infection in patients at high risk of recurrence.
-
Can Antibiotics Lead to Colon Cancer?
Swedish researchers saw an association between frequent antibiotic use and proximal colorectal cancer.
-
Functional Cognitive Disorder: An Important Condition to Recognize
Functional cognitive disorder (FCD) can describe cognitive difficulties that are present where there is no biologic cause, but a lack of consensus in diagnostic criteria limits its use in clinical practice and research. The authors proposed an operational definition for FCD as the cognitive phenotype of functional neurological disorder.
-
Combined GIP/GLP-1 Agonist: Safe for Type 2 Diabetes Patients?
In the SURPASS-2 trial, tirzepatide showed noninferiority and superiority vs. semaglutide in decreasing A1c levels in patients with type 2 diabetes.
-
Is This Ventricular Tachycardia?
The ECG in the figure was obtained from an elderly man with chest pain and shortness of breath. Is the rhythm ventricular tachycardia?
-
Insulin Glargine-yfgn Injection (Semglee)
-
Anticoagulation Plus Antiplatelet Therapy in Chronic Atherosclerosis
An analysis of the COMPASS trial for the secondary endpoint of mortality showed the combination of low-dose rivaroxaban and aspirin significantly lowered the all-cause mortality rate vs. low-dose aspirin alone.